India, Dec. 16 -- Biotechnology company PepGen Inc. (PEPG) announced Monday that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application to initiate the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular dystrophy (DMD).
The FDA indicated they will provide an official clinical hold letter to the Company within 30 days.
CONNECT2 is PepGen's Phase 2 multinational, double-blind placebo-controlled, multiple ascending dose, 25-week clinical trial of PGN-EDO51 in patients with DMD. The study is open in the United Kingdom.
PepGen is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the ...